Moderna shares jump 9.88% to touch $160

Moderna shares rose 9.88% during trading on 17 September 2026. The stock touched an intraday high of $160.00 after gaining $14.38 from its prior close of $145.62. Moderna issued no new clinical trial disclosures or press releases during the session.

The session gain pushed Moderna's share-price advance over the trailing 30 days to 137%. The stock traded near its 52-week peak of $176.66. Meanwhile, peer BioNTech saw its shares gain 1% on the day.

The rally follows momentum from August 2026, when Moderna shares surged 177% in a single day after the initial readout from a late-stage melanoma trial. That Phase 3 INTerpath-001 study enrolled 1,137 patients.

Wall Street analysts hold diverging price targets on the stock. Argus published a price target of $180.00 for Moderna, while Barclays set its price target at $125.00.